Adalimumab
- Level
- Commodity
- Parent
- 51202400
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51202401This classification denotes a monoclonal antibody and biological response modifier with the molecular formula C6428H9912N1694O1987S46, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) FYS6T7F842, more generally known as adalimumab. European Medicines Agency schedules adalimumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20016. The term ADALIMUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). As of Q4 2014, ADALIMUMAB remains US FDA's Preferred Term for this commodity. Adalimumab bears US NLM identifiers UMLS ID C1122087 and NCI Concept Code C65216. Most nations, for tariff and trade purposes, schedule adalimumab under HS 30021091 and SITC 54163. For the most current information on WCO designations on adalimumab and salts thereof, please see Committee proceedings HSC/27, NC0430B2 Ann. Q/1 (I) (2001). SMILES: none.
Same parent
Under 51202400 · 21Activities that produce or sell this
KBLI · 8Inherited from family 51200000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.